Again, I will return to the biomanufacturing strategy and life sciences strategy that's embedded with that because it's a good example of knitting together across multiple different departments and agencies the capacity to actually see something carried all the way through, and the engagement of corporate entities.
As the CIHR, we are part of that, but so are my colleagues here at the table, as well as ISED, in terms of helping with commercialization, and NRC. For us, the role of CIHR is to ensure that the investment is there in several different layers. The first is the early discovery component. We want to encourage working with my colleagues here through the tri-agency fund so that industry is brought in as a partner very early on, as well as the private sector. Then, moving into the clinical trials component to support that and to do the evaluative component, that needs to be done with industry as well.
The final piece is a rigorous training program to ensure that the next generation of researchers that we develop understand this pipeline in the context of working with public partners to make it successful.
Again, it's a very broad strategy, and each of us owns a piece of it.